Table 3.

Showing means and standard deviations (SDs) for mERG amplitudes and implicit times (IT) in rings 1–5 and combined ring 1–5 (R1–R5) at baseline and at an 18-month follow-up visit of 39 eyes, additionally, best corrected visual acuity (BCVA), central retinal thickness (CRT), difference Δ as well as the p-values for the Wilcoxon Signed Ranks Test

	Ring 1 (Ampl)	Ring 2 (Ampl)	Ring 3 (Ampl)	Ring 4 (Ampl)	Ring 5 (Ampl)	Ring 1 (IT)	Ring 2 (IT)
Baseline	17.5 ± 8.7	15.6 ± 6.7	13.6 ± 5.9	12.7 ± 5.3	13.4 ± 5.8	33.7 ± 5.7	32.4 ± 4.0
18-month follow-up	20.9 ± 11.3	16.1 ± 7.7	13.8 ± 6.6	12.6 ± 6.5	13.7 ± 8.1	33.7 ± 4.1	32.7 ± 3.0
Difference	3.4 ± 10.4	0.5 ± 7.3	0.2 ± 6.6	0.1 ± 6.9	0.3 ± 8.0	0.1 ± 7.4	0.3 ± 4.1
Δ p-value Wilcoxon Signed RanksTest	0.041	0.732	0.738	0.889	0.946	0.402	0.775

	Ring 3 (IT)	Ring 4 (IT)	Ring 5 (IT)	Combined R1–R5 (Ampl)	Combined R1–R5 (IT)	BCVA (letters)	CRT (µm)
Baseline	31.5 ± 3.4	31.2 ± 3.1	31.6 ± 3.3	19.0 ± 8.2	31.7 ± 3.3	65.1 ± 12.1	315.4 ± 89.5
18-month follow-up	31.6 ± 2.4	31.3 ± 2.3	31.6 ± 2.2	19.7 ± 10.8	31.6 ± 2.09	71.5 ± 9.2	222.3 ± 33.1
Difference	0.1 ± 3.4	0.1 ± 3.2	0.0 ± 3.2	0.6 ± 10.9	0.1 ± 3.2	6.4 ± 10.7	93.0 ± 82.8
Δ p-value Wilcoxon Signed RanksTest	0.994	0.729	0.827	0.878	0.922	0.001	0.000

p-value < 0.05 considered to be statistically significant